3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
6
Genitourinary
5
Other hematologic neoplasm
4
Lymphoid
4
Dermatologic
4
CNS
4
Thoracic
3
Gastrointestinal
3
Sarcoma
2
Gynecologic
2
Plasma cell
1
Breast
1
Conditions
Sarcoma
32
Melanoma
10
Osteosarcoma
8
Neoplasm Metastasis
8
Sarcoma, Kaposi
6
Leiomyosarcoma
6
Histiocytoma, Malignant Fibrous
6
Chordoma
6
Gliosarcoma
5
Colorectal Neoplasms
5
Carcinosarcoma
5
Carcinoma, Transitional Cell
5
Carcinoma, Renal Cell
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma, Ewing
4
Neuroblastoma
4
Neoplasms
4
Bone Neoplasms
4
Rhabdomyosarcoma
3
Neurofibrosarcoma
3
Lung Neoplasms
3
Hemangiosarcoma
3
Glioblastoma
3
Gastrointestinal Stromal Tumors
3
Endometrial Neoplasms
3
Desmoid Tumors
3
Cholangiocarcinoma
3
Interventions
Cyclophosphamide
39
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
30
Busulfan
26
Filgrastim
24
Cyclosporine
24
Mycophenolic Acid
22
Antilymphocyte Serum
22
Radiotherapy
20
Melphalan
16
Whole-Body Irradiation
15
Tacrolimus
14
Methylprednisolone
14
Methotrexate
13
Cord Blood Stem Cell Transplantation
12
Etoposide
10
sargramostim
5
Thiotepa
5
Temozolomide
5
Sirolimus
5
Rituximab
5
Bevacizumab
5
aldesleukin
4
Therapeutics
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
Carmustine
4
pembrolizumab
3
Vincristine
3
Topotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
Nivolumab
×
Sarcoma
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts